AP4 This associate program of PMS-ICBG will test natural products identified in AP3 for their pharmaceutical potential in treating several important diseases. We have selected our disease targets by considering:1) unmet needs in human health;2) health needs in the Philippines;3) assays that have a strong tie to our eco-rationale and symbiosis studies in AP2;4) that provide a mix of innovative and conservative approaches to drug discovery. Our assays target conditions that involve neuronal receptors, ion channels, and other proteins; pancreatic cancer;glioblastoma;pandrug-resistant """"""""ESKAPE"""""""" infections;and apicomplexan parasite infections, with a focus on Crytosporidium and Toxoplasma. Further, we have formed interactions with appropriate entities that have further assays available and that are well suited to help us translate discoveries into products that will have a positive impact on human health. A particularly innovative focus of this AP is our use of the recently invented """"""""constellation pharmacology"""""""" method, which provides a method for high-content screening against naturally differentiated mammalian cell types. Preliminary data show that this method is very promising in finding ligands for very challenging targets, and here we will take that further by screening natural products. This and other innovative methods proposed are reinforced with time-tested approaches to drug discovery to provide a relatively comprehensive screening of our library. Finally, we have developed strategies to validate hits and to determine their translational potential early on in studies. Promising candidates will be further investigated as part of this program. To achieve these goals, we plan to: 1) Screen priority extracts from AP3; 2) Employ constellation screening for neurological and cancer drug discovery; 3) Employ novel assays for antibiotic discovery; 4) Employ novel assays against parasites; 5) Identify molecular targets and further develop compounds.
AP4 This associate program of the PMS-ICBG will test extracts, fractions and pure compounds provided by AP3 in a variety of assays aimed at the development of pharmaceuticals to treat human disease. We are screening against disease conditions that include, but are not limited to: neurological conditions, cancers, including pancreatic cancer and glioblastoma, pandrug-resistant bacterial infections, and infections by apicomplexan parasites.
|Barghi, Neda; Concepcion, Gisela P; Olivera, Baldomero M et al. (2015) Comparison of the Venom Peptides and Their Expression in Closely Related Conus Species: Insights into Adaptive Post-speciation Evolution of Conus Exogenomes. Genome Biol Evol 7:1797-814|
|Neves, Jorge L B; Lin, Zhenjian; Imperial, Julita S et al. (2015) Small Molecules in the Cone Snail Arsenal. Org Lett 17:4933-5|
|Cragg, Simon M; Beckham, Gregg T; Bruce, Neil C et al. (2015) Lignocellulose degradation mechanisms across the Tree of Life. Curr Opin Chem Biol 29:108-19|
|Barghi, Neda; Concepcion, Gisela P; Olivera, Baldomero M et al. (2015) High conopeptide diversity in Conus tribblei revealed through analysis of venom duct transcriptome using two high-throughput sequencing platforms. Mar Biotechnol (NY) 17:81-98|
|Lin, Zhenjian; Koch, Michael; Abdel Aziz, May Hamdy et al. (2014) Oxazinin A, a pseudodimeric natural product of mixed biosynthetic origin from a filamentous fungus. Org Lett 16:4774-7|
|Olivera, Baldomero M; Showers Corneli, Patrice; Watkins, Maren et al. (2014) Biodiversity of cone snails and other venomous marine gastropods: evolutionary success through neuropharmacology. Annu Rev Anim Biosci 2:487-513|
|Imperial, Julita S; Cabang, April B; Song, Jie et al. (2014) A family of excitatory peptide toxins from venomous crassispirine snails: using Constellation Pharmacology to assess bioactivity. Toxicon 89:45-54|